A multicentre open-label phase IIa study with escalating dose of MS1819-SD, to investigate the efficacy and safety of a Yarrowia lipolytica lipase preparation for the compensation of exocrine pancreatic insufficiency caused by chronic pancreatitis and/or distal pancreatectomy.

Trial Profile

A multicentre open-label phase IIa study with escalating dose of MS1819-SD, to investigate the efficacy and safety of a Yarrowia lipolytica lipase preparation for the compensation of exocrine pancreatic insufficiency caused by chronic pancreatitis and/or distal pancreatectomy.

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jun 2018

At a glance

  • Drugs Lipase (Primary)
  • Indications Exocrine pancreatic insufficiency; Pancreatitis
  • Focus Adverse reactions
  • Acronyms MS1819-SD
  • Sponsors AzurRx BioPharma
  • Most Recent Events

    • 29 Jun 2018 According to the AzurRx BioPharma media release, company expects to formally report the data from this study in the Fall of 2018.
    • 29 Jun 2018 Status changed from recruiting to completed, according to the AzurRx BioPharma media release.
    • 23 Apr 2018 Results (n=9) published in an AzurRx BioPharma Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top